Euro Pacific Asset Management LLC Cuts Position in Haleon plc (NYSE:HLN)

Euro Pacific Asset Management LLC reduced its position in Haleon plc (NYSE:HLN) by 1.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 96,917 shares of the company’s stock after selling 1,836 shares during the period. Euro Pacific Asset Management LLC’s holdings in Haleon were worth $1,032,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HLN. Manning & Napier Advisors LLC acquired a new position in shares of Haleon during the second quarter worth $2,833,000. Sei Investments Co. raised its stake in Haleon by 79.1% in the first quarter. Sei Investments Co. now owns 781,089 shares of the company’s stock valued at $6,632,000 after buying an additional 345,036 shares during the last quarter. Magnetar Financial LLC acquired a new stake in Haleon in the first quarter worth about $853,000. Cetera Advisors LLC grew its stake in shares of Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after acquiring an additional 68,857 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Haleon by 106.3% during the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after acquiring an additional 120,447 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

HLN opened at $9.39 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The firm has a 50 day moving average of $10.10 and a two-hundred day moving average of $9.33. The firm has a market capitalization of $42.51 billion, a PE ratio of 27.62, a P/E/G ratio of 2.79 and a beta of 0.30.

Analyst Ratings Changes

HLN has been the subject of a number of recent analyst reports. Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Berenberg Bank initiated coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haleon presently has an average rating of “Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.